Antengene Corporation Limited
Prices may be delayed up to 15 min. Not investment advice. News volume: articles about it in the 4Search index. Click a dot on the chart for the event and the news of that day.
Key statistics
Against its peers
Compare in full ›| 722.F | ADAG | ALXO | ATORX.ST | MGNX | PYXS | |
|---|---|---|---|---|---|---|
| Market cap | 151.02M | 118.17M | 137.03M | 28.54M | 125.26M | 216.49M |
| P/E (TTM) | 24.8 | — | — | — | — | — |
| Forward P/E | — | -3.1 | -2.0 | -0.1 | -1.2 | -2.2 |
| Price/book | 1.3 | 1.3 | 1.2 | 0.2 | 5.0 | 3.7 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −42.06% | +11.67% | −28.67% | −99.06% | +41.43% | −64.85% |
| Today | −8.15% | −12.44% | +3.92% | −5.88% | −1.01% | +7.74% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All 722.F news ›Antengene Presents Latest Clinical Results for ATG-022 and ATG-037 at ESMO 2026
SHANGHAI and HONG KONG, /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class…
Antengene Highlights Pre-Clinical Data Of Treg-Inducing Autoimmune Candidate ATG-207
Antengene Corporation Ltd. (6996.HK), a commercial-stage global biotech company focused on medicines for autoimmune diseases, solid tumours, and haematological malignancies, presented the latest preclinical results of ATG-207 at the 2026…
Antengene Presents Latest Preclinical Results of Novel Cos-TCE Platform AnTenGager‑D2 in Rapid Oral Abstract Presentation at SITC 2026
SHANGHAI and HONG KONG, Nov. 8, 2026 /PRNewswire/ -- Antengene Corporation Limited ('Antengene', SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing…
Antengene Announces First Patient Dosed in Phase I ATTRACT Study Evaluating ATG-201 (CD19 × CD3 TCE) for B Cell-Mediated Autoimmune Diseases
The Phase I ATTRACT study is being conducted in China and Australia. In parallel with the study’s advancement in China, ATG-201 has obtained approval from the Human Research Ethics Committee (HREC) in Australia, and completed the Clinical…
XPOVIO® (selinexor) Approved for Commercialization in Indonesia, Further Expanding Antengene's Commercial Presence in APAC
05 Mar, 2025, 13:00 CST - XPOVIO® is the first and only approved XPO1 inhibitor in Indonesia. - From the second half of 2024 to now, XPOVIO® was successively approved in Thailand, Malaysia and Indonesia, significantly expanding Antengene's…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- prnewswire.com2
- herald-dispatch.com1
- jdnews.com1
- macaubusiness.com1
- tigersroar.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 6 articles, not a forecast.